ReviewMaterials today. Bio2025
Structure-centered design of lipid-based nanocarriers to overcome biological barriers.
Review in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Layer by Layer Engineered Lipid-Based Nanocarriers for Therapeutic Delivery and Next-Generation Design.Pharmaceutics · 2026Review
- Polyphenol-Loaded Liposomal Nanocarriers fromMolecules (Basel, Switzerland) · 2026Article
- Bridging the "Valley of Death" in Antifungal Therapy: Next-Generation Biomimetic and Exosome-Inspired Nanocarriers for Invasive Candidiasis.Journal of fungi (Basel, Switzerland) · 2026Review
- Animal- and Plant-Derived Protein Nanocarriers for the Delivery of Natural Compounds in Breast Cancer Chemoprevention.Molecules (Basel, Switzerland) · 2026Review
- Recent progress of plant-derived extracellular vesicle-like nanoparticles integrated with biomaterials for skin repair.Journal of nanobiotechnology · 2026Review
- Biomaterials for Improving Skin Penetration in Treatment of Skin Cancer.Journal of functional biomaterials · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As technology has evolved in response to pressing human challenges, drug delivery systems (DDSs) have also evolved to overcome complex biological barriers. Particularly, the continuous development of therapeutic strategies has enabled the integration of nanotechnology, leading to the emergence of diverse nanoscale DDSs. Concerns about the potential toxicity of nanomedicines diverted attention to lipid-based nanocarriers (LBNs), regarded as safer and more biocompatible platforms. In this review, the structural evolution of LBNs is categorized into three stages according to the increasing functional complexity required to address biological barriers, providing a framework to understand how designs advanced with physiological demands. This trajectory encompasses emulsions and LBNs, with each stage advanced by strategies such as lipid composition tuning, surface functionalization, biomimetic construction, and hybridization with other platforms. Over a few decades, this transition has described that the progression of LBNs reflects not merely chronological advances but a stepwise evolution of structural adaptations shaped by biological barriers. This analytical perspective is presented through a comprehensive discussion of the structural strategies utilized in recent LBN research. Consequently, structural evolution provides a foundation for refining design approaches in drug delivery and achieving improved therapeutic outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.